Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018
Clinical trial NCT05228613 · COMPLETED
Trial details
- NCT number
- NCT05228613
- Sponsor
- PT Bio Farma
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-16
- Primary completion
- 2022-08-02
- Enrollment
- 175
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.